Antimicrobial resistance (AMR) has emerged as one of the most urgent global public health threats of the twenty-first century[1]. The rapid dissemination of resistant bacterial strains has progressively compromised the effectiveness of existing antimicrobial therapies, a process largely driven by the excessive, inappropriate, and prolonged use of antibiotics in both clinical and agricultural settings [2][3]. As a result, common infections are becoming increasingly difficult to treat, with rising morbidity, mortality, and healthcare costs. Microorganisms have evolved diverse adaptive strategies to counter antimicrobial pressure, including enzymatic inactivation of drugs, modification of molecular targets, efflux pump overexpression, and biofilm formation, all of which collectively reduce antibiotic susceptibility and therapeutic efficacy [4][5][6].
In response to this accelerating crisis, the identification of alternative antimicrobial resources has become a strategic research priority. Natural products, in particular, offer structurally diverse bioactive molecules that frequently exhibit novel modes of action distinct from those of conventional antibiotics[7][8]. Among these, antimicrobial peptides (AMPs) have attracted sustained attention due to their broad-spectrum activity, rapid bactericidal kinetics, low propensity for resistance development, and capacity to target bacterial membranes and intracellular machinery simultaneously[9][10]. Beyond peptides, complex biological matrices derived from invertebrates, plants, and marine organisms have increasingly been explored as reservoirs of multifunctional antimicrobial agents[7].
Snails represent a largely underexplored biological group in this context. Constantly exposed to microbial contamination, mechanical injury, and environmental stressors, these organisms have evolved highly efficient innate defense mechanisms. A central component of this defense is mucus, a viscoelastic secretion that functions as a physical barrier, a lubricant, and a chemically active antimicrobial interface[11][12]. Snail mucus, in particular, has long been recognized for its biological properties, including antimicrobial, anti-inflammatory, and wound-healing effects, and has been traditionally exploited in cosmetic and folk medicinal applications [13][14][15]. Contemporary biochemical and microbiological investigations have begun to substantiate these empirical observations, revealing that snail mucus contains a complex repertoire of antimicrobial peptides, glycoproteins, lectins, enzymes, and bioactive polysaccharides capable of inhibiting a wide range of bacterial, fungal, and viral pathogens.
Experimental studies across terrestrial, freshwater, and marine snail species have consistently demonstrated the antimicrobial activity of snail mucus against clinically relevant microorganisms. Early work by Rajaganapathi et al reported inhibitory effects against Salmonella typhi[16], while López et al isolated bactericidal proteins from the marine mollusk Cenchritismuricatus[17].Subsequent studies involving species such as Hemifususpugilinus, Pila virens, Helix aspersa, and Achatina fulica further confirmed broad-spectrum antimicrobial efficacy and antibiofilm activity[18][19]. Recently, snail mucus, its proteins, and molecular components have attracted greater attention in the scientific community[20][21]. They are being studied not only for their antibacterial properties, but also for their antiviral and antifungal effects[22]. The antimicrobial properties of raw mucus and its various fractions have been recorded against a multitude of microorganisms, supporting the idea that this natural secretion could be used in the medical, biotechnological, and cosmetic fields, or even as a natural ingredient in the food industry[20][23][24].
In parallel with molecular investigations, snail mucus has recently attracted attention as a functional biological matrix for the green synthesis of nanomaterials[25]. The mucins, peptides, and proteins present in mucus can act simultaneously as reducing, capping, and stabilizing agents during nanoparticle formation, enabling the fabrication of metallic and carbonaceous nanostructures under mild, environmentally benign conditions[26][27][28]. These biogenic nanoparticles often display enhanced antimicrobial activity relative to their chemically synthesized counterparts, owing to synergistic interactions between the nanomaterial core and the bioactive mucus-derived surface corona[25][26][27]. This convergence of natural product chemistry and nanotechnology has opened new avenues for developing hybrid antimicrobial platforms with improved efficacy and biocompatibility[29].
Despite the growing body of literature on snail mucus bioactivity, existing studies remain fragmented across biochemistry, microbiology, nanotechnology, and biomedical engineering disciplines. Most reports focus narrowly on isolated antimicrobial effects, individual peptide fractions, or specific nanoparticle formulations, without integrating these findings into a unified conceptual framework. Consequently, the relationships between mucus molecular composition, antimicrobial mechanisms, and nanotechnological applications remain insufficiently synthesized and critically assessed.
The present review addresses this gap by systematically integrating current evidence on the antimicrobial properties of snail mucus, its molecular constituents, and its role in the biosynthesis of functional nanomaterials. We critically examine antibacterial, antifungal, and antiviral activities across snail species, characterize the structural diversity of mucus-derived peptides, proteins, and polysaccharides, and analyze mechanistic pathways involving membrane disruption, oxidative stress, and virulence inhibition. In addition, we evaluate the physicochemical and biological features of mucus-mediated nanoparticles and discuss translational implications for wound healing, biomaterials, and emerging anti-infective therapies. By unifying molecular, mechanistic, and nanotechnological perspectives within a single biomedical framework, this review aims to clarify the therapeutic potential of snail mucus and to delineate key research priorities necessary for its progression toward clinical and industrial applications.
The graphic abstract in Figure 1 shows the main points identified in the article, from ways of using snail mucus as an antibacterial, antifungal, and antiviral agent to the use of the nanocomposites it contains as antimicrobials,and its various applications in medicine.
Figure 1: Graphical abstract
1. ANTIBACTERIAL ACTIVITIES OF SNAIL MUCUS
Snail mucus constitutes a biologically active matrix with reproducible antibacterial properties that have been documented across a wide range of terrestrial, freshwater, and marine snail species [30][31]. Its antibacterial efficacy is not uniform but varies as a function of species, pigmentation, physiological state, extraction protocol, and the physicochemical characteristics of the tested fractions [32][33]. In several experimental systems, mucus-derived preparations have demonstrated inhibitory effects comparable to, and in some cases exceeding, those of reference antibiotics, underscoring their potential relevance as alternative antibacterial agents[34][35].
Both Gram-positive and Gram-negative bacteria are susceptible to snail mucus, although sensitivity profiles differ markedly between species and mucus fractions. Reported inhibition zone diameters range from negligible values to over 60 mm, while minimum inhibitory concentrations (MICs) span approximately 0.2 μg/mL to 128 μg/mL, reflecting substantial heterogeneity in antimicrobial potency[36][37][38][39]. Aqueous extracts frequently outperform ethanolic and organic fractions, suggesting that hydrophilic peptides, glycoproteins, and oxidative enzymes are primary contributors to antibacterial activity. For example, Adole et al. reported that aqueous mucus extracts exerted stronger inhibitory effects than ethanolic fractions against Bacillus subtilis, Staphylococcus aureus, Salmonella typhi, and Escherichia coli[32].
Among the best-characterized species, Helix aspersa mucus has consistently demonstrated robust antibacterial performance. Inhibition zones ranging from approximately 19 to 25 mm have been reported against multiple bacterial strains, with corresponding MIC and minimum bactericidal concentration (MBC) values between 3.12 and 6.25% (v/v) and MBC/MIC ratios of 1-2, indicating a predominantly bactericidal mode of action[40]. Time-kill kinetic analyses further support this conclusion. In addition to direct antibacterial effects, H. aspersa mucus exhibits marked antibiofilm activity, inhibiting biofilm formation by 88–95% and eradicating established biofilms by up to 91% [40]. This dual antibacterial and antibiofilm capacity is particularly relevant in the context of chronic and device-associated infections[41][42].
Beyond H. aspersa, antibacterial activity has been documented in the mucus of multiple snail species. Water-soluble fractions and mucins from Achatina fulica inhibit both Gram-positive and Gram-negative bacteria, including B. subtilis, S. aureus, E. coli, and Pseudomonas aeruginosa[39]. Similar effects have been observed in species such as Hemifususpugilinus, Pila virens, and Cenchritismuricatus, reinforcing the generalizability of mucus-mediated antibacterial defense across gastropods [17][18][19].
Comparative studies reveal pronounced interspecies and intraspecies variability in antibacterial efficacy. The mucus of Eobania desertorum has been reported to exhibit stronger inhibitory effects against burn-associated multidrug-resistant strains than that of H. aspersa[43]. Within Archachatina marginata, the ovum variety demonstrates greater activity against Pseudomonas spp. and Streptococcus spp., whereas the saturalis variety more effectively inhibits Staphylococcus spp. [44]. Pigmentation also appears to influence antibacterial potency: mucus from normally pigmented snails generally shows higher activity against Staphylococcus spp., Pseudomonas spp., and Salmonella spp., whereas mucus from albino individuals displays enhanced activity against E. coli[44]. These differences likely reflect quantitative and qualitative variation in peptide composition, mucin content, and oxidative enzyme abundance. Table 1 confirms the antibacterial capacity of mucus in other snail species against Gram-positive and Gram-negative bacteria, with particularly interesting inhibition zone diameters and minimum inhibitory concentrations.
Collectively, these findings indicate that the antibacterial activity of snail mucus is strongly species-dependent and fraction-specific, with aqueous extracts and low-molecular-weight peptide-rich fractions consistently outperforming crude or organic preparations. Antibiofilm efficacy and bactericidal potency correlate with peptide composition, mucin abundance, and the presence of oxidative enzymes, rather than with total protein content alone. At the same time, substantial methodological heterogeneity -encompassing extraction procedures, assay formats, pH conditions, and bacterial inoculum densities-limits cross-study comparability and complicates quantitative benchmarking. These limitations underscore the need for standardized evaluation frameworks to accurately assess the therapeutic potential of mucus-derived antibacterial agents and to enable rational selection of species and fractions for translational development.
Table 1: The antibacterial activity of snail mucus is expressed by the average diameter of the pathogen inhibition zones generated by snail mucus and the minimum inhibitory concentration.
|
Snails |
Part of mucus tested |
Bacteria tested |
Zone of inhibition |
MIC |
Ref |
|
Helix aspersa (Müller, 1774)
|
Mucus |
P. aeruginosa E. coli (ATCC 35218) L. monocytogenes (ATCC 7644) Staphylococcus aureus (ATCC 29213) |
23,1 mm 30,0 mm 11,1 mm 12,3 mm |
100 µg/mL 100 µg/mL 100 µg/mL 100 µg/mL |
[13] |
|
Hemocyanin β c-HaH |
E. coli P. aeruginosa St aureus Ent. Faecium St epider- mid |
30?% 175?% 30?% 275?% 30 %g |
- - - - - |
[25]
|
|
|
Mucus |
Streptococcus pyogenes NCIMB 13285 Pseudomonas aeruginosa NCTC 8626 Pseudomonas aeruginosa NCTC 10548 |
5.5?mm 11.12 mm 11.63 mm |
- - - |
[45] |
|
|
Mucus |
Streptococcus aureus ATCC 25923 E. coli ATCC 25922 |
>50?µg/µl 25?µg/µl |
- - |
[46] |
|
|
Mw>20 kDa (2 730) |
E. coli ou B. diminuta Brevindomonasdiminita |
- - |
145 - 682,5μg/ml 290 - 431,5 μg/ml |
[47] |
|
|
Mucus |
Staphylococcus aureus |
9,33 - 12,00 mm |
25 % (v/v) |
[40] |
|
|
Mucus |
P. aeruginosa (PA-9) E. coli (EC-3) Pneumonie à K. (KP-1) Staphylococcus aureus (SA-17) |
15,8 mm 16,8 mm 0,0 mm 18,2 mm |
15(µg/ml) 20 ND 15 |
[43] |
|
|
1:3 diluted mucous |
Streptococcus pyogenes NCIMB 13285 Pseudomonas aeruginosa 8626 Pseudomonas aeruginosa 10548 |
5.5 mm 11.12 mm 11.63 mm |
- - - |
[41] |
|
|
Achatina marginata
|
Mucus |
Bacillus subtilis Salmonella typhi |
24,83 mm 19,00 mm |
- |
[48] |
|
Mucus |
S. aureus |
17 mm |
- |
[49] |
|
|
Archachatina marginata |
Mucus |
Staphylococcus aureus MRSA Escherichia coli Proteus mirabilis Pseudomonas aeruginosa Klebsiella sp |
14.34 mm 0.00 mm 17.34 mm 15.34 mm 15.67 mm 16.34 mm |
50MIC(v/v) NA 25MIC(v/v) 25 MIC (v/v 25 MIC (v/v 25 MIC (v/v |
[50] |
|
Archachatina marginata [albino skinned] |
Mucus |
E. coli Sal. Spp St aureus P. spp |
0.050?µg/ml 0.098?µg/ml 100?µg/ml 100?µg/ml |
- - - - |
[51]
|
|
Archachatina marginata [normal skinned] |
Mucus |
E. coli Sal. Spp St aureus P. spp |
0.098?µg/ml 0.049?µg/ml 50?µg/ml 50?µg/ml |
- - - -
|
[51][51]
|
|
Archachatina marginata saturalis |
Mucus |
Staphylococcus sp Pseudomonas sp Streptococcus sp |
17.4 mm 19.2 mm 18.6 mm |
100 20 40 |
[44]
|
|
Archachatina marginata ovum |
Mucus |
Staphylococcus sp Pseudomonas sp Streptococcus sp |
15.6 mm 19.8 mm 19.3 mm |
80 60 40 |
[44]
|
|
Achatina fulica
|
Mucus |
Staphylococcus spp Pseudomonas sp Streptococcus sp Staphylococus aureus Staphylococus epidermidis |
15.4 mm 17.1 mm 17.5± mm 9.30 mm 10.29 mm |
- - - - - |
[44]
[52] |
|
Protein |
H. alvei S. marcescens Staphylococcus |
11 mm 14 mm 15,5 mm |
100µg/mL 100µg/mL 100µg/mL |
[19] |
|
|
FMA30 (Mw > 30 kDa) |
Staphylococcus aureus |
- |
9 µg/mL |
[53] |
|
|
FME30 (Mw 30–10 kDa) |
Staphylococcus aureus |
- |
120 µg/mL |
[53] |
|
|
Achacin |
E. coli IFO 12734 St aureus IFO 12732 |
24?µg/ml 5?µg/ml |
- - |
[54]
|
|
|
Mucus |
E. coli IAM 1011 St aureus K12 W3110 |
2?µg/ml 0.2?µg/ml |
- - |
[55]
|
|
|
Mucus |
Strep. agalactiae ATCC 12403 Strep. agalactiae ATCC 12403 St aureus MRSAe E. coli E. coli |
2.1?mg/ml 3.6?mg/ml 3.3?mg/ml 2.4?mg/ml 3.8?mg/ml |
- - - - - |
[56]
|
|
|
Achatina CRP |
B. subtilis MTCC 121 St aureus MTCC 96 E. coli MTCC 68 P. aeruginosa MTCC 741 Pn. ananatis MTCC 2307 Lis. Monocytogenes MTCC 637 St epidermidis MTCC 2639 Sal. typhimurium MTCC 98
|
18?mm 14?mm 12?mm 11?mm 12?mm 13?mm 12?mm 15?mm |
- - - - - - - -
|
[57]
|
|
|
Mytimacin-AF |
E. coli ATCC 25922 St aureus ATCC 25923 B. pyocyaneus CMCCB 10104 B. megatherium B. dysenteriae K. pneumoniae |
7.5?µg/ml 1.9?µg/ml 3.75?µg/ml 15?µg/ml 3.75?µg/ml 30?µg/ml |
- - - - - - |
[58]
|
|
|
Mucus |
S. aureus E. coli |
- - |
0.2 μg/ml 2 μg/ml |
[38] |
|
|
Mucus |
S. aureus S. epidermidis |
13.15 mm 15.20 mm |
20 μg/ml 20 μg/ml |
[58] |
|
|
Slime Fractions Aqueous |
S. aureus E. coli S. typhi B. subtilis |
23.13 mm 15.13 mm 19.40 mm 15.07 mm |
3.125 (%) 3.125 (%) 6.25 (%) 3.125 (%) |
[32] |
|
|
Slime Fractions Ethanolic |
S. aureus E. coli S. typhi B. subtilis |
14.20 mm 11.80 mm 13.47 mm 10.67 mm |
3.125 (%) 3.125 (%) - 3.125 (%) |
||
|
Protein 83. kDa 50.81 kDa 15 kDa 11.45 kDa 9.7 kDa |
Streptococcus mutans |
18.26 mm 18.76 mm 15.51 mm 0 mm 0 mm |
- - - - - |
[59] |
|
|
Protein 83. kDa |
Aggregatibacteractinomycetemcomitans |
11.26 mm 13.69 mm 12.34 mm 11.38 mm 0 mm |
- - - - -
|
||
|
50.81 kDa |
|||||
|
15 kDa |
|||||
|
11.45 kDa |
|||||
|
9.7 kDa |
|||||
|
Mucus |
Enterococcus foecalis |
21.9 |
- |
[60] |
|
|
Mucus |
Pseudomonas aeruginosa Klebsiella pneumonia Escherichia coli Staphylococcus aureus |
30 mm 46 mm No 38 mm |
- - - - |
[61] |
|
|
Mucus (20µL) |
Staphylococus aureus |
13.15 mm |
- |
[62] |
|
|
Mucus |
Fusobacterium nucleatum |
19.60 mm |
- |
[63] |
|
|
Mucus |
A. actinomycetemcomitans |
17.90 mm |
- |
[64] |
|
|
Pila globosa |
Mucus |
Staphylococcus |
15,83 ± 0,76 |
100µg/mL |
[19] |
|
Achantina fulica |
Mucus |
Escherichia coli PBR 322 Vibrio cholerae |
21 mm 16 mm |
- - |
[65] |
|
Lissachatina fulica |
Mucus
|
S. aureus MRSA S. epidermidis Corynebacterium spp |
14.83 mm 17.51 mm 15.87 mm 15.73 mm |
- - - - |
[66]
|
|
Pomacea canaliculata |
Mucus |
S. aureus MRSA S. epidermidis Corynebacterium spp |
12.03 mm 13.60 mm 11.07 mm 13.35 mm |
- - - - |
[66] |
|
Pila virens |
Mucus |
Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Salmonella typhi Klepsiella pneumoniae |
10-11 mm 9-11 mm 10-11 mm 9 mm 9-10 mm |
- - - - - |
[18] |
|
Cornu aspersum |
Mucus (Fraction from 1 to 10 kDa) |
P. aeruginosa AP9 B. laterosporus BT271 |
15 mm 12 mm |
13.1 mg/ml |
[67]
|
|
Eobania vermiculata |
Mucus |
Enterococcus faecalis Pseudomonas aeruginosa Acinetobacter baumanii Escherichia coli Staphylococcus aureus |
45 mm 49mm 44mm 37mm 48mm |
128 µg/mL 64 128 128 64,0 |
[36] |
|
AgNPs-SM |
Enterococcus faecalis Pseudomonas aeruginosa Acinetobacter baumanii Escherichia coli Staphylococcus aureus |
60 mm 65 mm 50 mm 52 mm 58 mm |
4 2 32 16 16 |
||
|
Eremina desertorum |
Mucus |
P. aeruginosa (PA-9) E. coli (EC-3) Pneumonie à K. (KP-1) Staphylococcus aureus (SA-17) |
25,5 mm 30,5 mm 0,0 mm 28 mm |
7 5 ND 5 |
[37] |
|
Theba pisana |
Mucus |
Staphylococcus aureus Escherichia coli Klebsiella pneumoniae Enterococcus faecalis SARM |
16 mm 12 mm 16 mm 24 mm 14 mm |
- - - - - |
[30] |
|
Crypozonabistrali |
Mucus |
Pseudomonas aeruginosa Klebsiella pneumonia Escherichia coli Staphylococcus aureus |
No No 19 mm No |
- - - - |
[61] |
2. ANTIFUNGAL ACTIVITY OF SNAIL MUCUS
Snail mucus represents a biologically rich source of antifungal biomolecules that has attracted increasing attention in the context of rising resistance to conventional antifungal drugs [42]. Fungal infections constitute a growing public health burden, particularly among immunocompromised populations, and the limited diversity of existing antifungal classes has intensified interest in natural products with novel mechanisms of action. In this regard, peptides, proteins, and glycoproteins derived from snail mucus have demonstrated inhibitory activity against a range of pathogenic yeasts and filamentous fungi, positioning snails as a promising reservoir of antifungal agents [68].
Land snail species have yielded particularly compelling evidence of antifungal efficacy. Mucin isolated from Archachatina marginata inhibited the growth of Candida albicans, producing an inhibition zone of approximately 12 mm at a concentration of 30% [49]. Antimicrobial peptides extracted from Achatina fulica, notably mytimacin-AF, exhibited pronounced antifungal activity, with a minimum inhibitory concentration of 7.5 μg/mL against C. albicans[42][69]. By contrast, mucus from Helix aspersa failed to show measurable inhibitory effects against this yeast under comparable experimental conditions[42], highlighting substantial interspecies variability in antifungal potency.
Comparative proteomic analyses further substantiate this species-dependent heterogeneity. Ulagesan et al. examined protein fractions from seven terrestrial snail species and reported that proteins from Cryptozona bistrialis almost completely suppressed the growth of tested fungal pathogens, even at low concentrations [19]. These findings indicate that antifungal activity is not uniformly distributed across snails but instead reflects differential expression of bioactive proteins and peptides with distinct molecular architectures and modes of action.
Beyond growth inhibition, mechanistic studies have begun to elucidate intracellular effects associated with mucus-derived antifungal activity. Protein fractions (MCa/1–20) isolated from Cornu aspersum mucus exhibited strong inhibitory effects against Penicillium griseofulvum and Aspergillus niger, primarily through disruption of membrane integrity and induction of cellular leakage of proteins and reducing sugars [70]. These effects were accompanied by elevated lipid peroxidation and oxidative protein damage, together with suppression of endogenous antioxidant enzyme defenses, indicating that oxidative stress represents a central mechanism of antifungal action in these systems [70].
Marine snails also contribute to the diversity of mucus-derived antifungal agents. A crude extract of Cenchritismuricatus yielded a bioactive peptide of 1485.26 Da, subsequently purified, sequenced, and chemically synthesized. This peptide, designated Cm-p1 (SRSELIVHQR), demonstrated inhibitory activity against both yeasts and filamentous fungi[71]. Structural modeling suggests that Cm-p1 adopts a hydrophilic α-helical conformation with a cationic residue that facilitates interaction with fungal membranes, thereby promoting membrane destabilization as a plausible mechanism of action. The table2 below represents the antifungal activity of the snail mucus of different types of these snails against different types of fungi.
Table 2. Antifungal activity of snail mucus against various yeasts and fungi. The diameter of the inhibition zone and the minimum inhibitory concentration (MIC) are shown for each fungus.
|
Snails |
Microorganisms |
Fraction tested |
Inhibition zone) |
CMI |
Ref
|
|
Achatina fulica |
C. albicans |
Protein |
15,5 mm |
100 µg/mL |
[19] |
|
P. chrysogenum |
Protein |
11,83 mm |
100 µg/mL |
[19] |
|
|
A. fumigatus |
Protein |
12,3 mm |
ND |
[19] |
|
|
Cryptozona bistrialis |
C. albicans |
Protein |
15,83 mm |
25µg/mL |
[19] |
|
P. chrysogenum |
Protein |
19,83 mm |
25µg/mL |
[19] |
|
|
A. fumigatus |
Protein |
24,6 mm |
12.5µg/mL |
[19] |
|
|
M. racemosus |
Protein |
21 mm |
12.5µg/mL |
[19] |
|
|
Pila globosa |
A. fumigatus |
Protein |
11,6 mm |
ND |
[19] |
|
M. racemosus |
Protein |
20 mm |
ND |
[19] |
|
|
Pila virens |
C. albicans |
Protein |
9 mm |
100 µg/mL |
[19] |
|
P. chrysogenum |
Protein |
10,5 mm |
ND |
[19] |
|
|
A. fumigatus |
Protein |
11 mm |
ND |
[19] |
|
|
M. racemosus |
Protein |
10 mm |
ND |
[19] |
|
|
Bellamya dissimilis |
M. racemosus |
Protein |
20 mm |
ND |
[19] |
|
Bithynia pulchella |
P. chrysogenum |
Protein |
9 mm |
ND |
[19] |
|
Cenchritismuricatus |
Botrytis cinerea Fusaryumoxysporum Aspergillus niger Candida albicans 01U Candida albicans 38U Parasilose à Candida Cryptococcusneoformans L26 Cryptococcusneoformans L30 Trichophyton rubrum |
Mucus |
20mm 20mm 41mm 13mm 7mm 105mm 209mm 209mm 3mm |
ND ND ND ND ND N D ND ND ND |
[71] |
Taken together, these findings indicate that snail mucus harbors a structurally diverse repertoire of antifungal biomolecules whose activity is strongly species-dependent and fraction-specific. Land snails such as Achatina fulica and Cryptozona bistrialis emerge as particularly potent sources of antifungal peptides and proteins, whereas other species display limited or negligible activity against certain fungal targets. Mechanistically, antifungal effects are mediated not only by membrane perturbation but also by the induction of intracellular oxidative stress and metabolic disruption. However, substantial variability in experimental protocols, concentration units, and assay formats complicates quantitative comparison across studies. These limitations underscore the need for standardized antifungal screening frameworks and systematic structure-activity correlation analyses to enable rational selection of mucus-derived antifungal candidates for translational development.
3. ANTIVIRAL ACTIVITY OF SNAIL MUCUS
In recent years, snail mucus and its bioactive constituents have attracted growing interest for their potential antiviral properties, extending the biomedical relevance of snail secretions beyond antibacterial and antifungal applications. Although antiviral investigations remain comparatively limited, accumulating evidence indicates that both raw mucus and isolated molecular fractions can interfere with viral entry, replication, and host-virus interactions, thereby positioning snail mucus as a candidate source of novel antiviral agents [42].
Snail mucus is enriched in proteins, peptides, and glycopeptides with established biological activity, several of which exhibit structural features compatible with antiviral function [28][35]. Among these, antimicrobial peptides (AMPs) represent a prominent class of host defense molecules capable of interacting with viral envelopes, blocking viral fusion, and modulating host immune responses [35]. Computational screening and predictive analyses have identified multiple mucus-derived peptide sequences with high antiviral potential, including GAACNLEDGSCLGV, NGLFGGLGGGGHGGGGKGPGEGGG, and LLLLMLGGGLVGGLLGGGGKGGG[72]. While these in silico predictions require experimental validation, they underscore the latent antiviral capacity embedded within the mucus peptide repertoire.
A particularly compelling antiviral component of snail mucus is acharan sulfate, a heparin-like sulfated glycosaminoglycan isolated from the mucus of Achatina fulica. This polysaccharide has demonstrated the capacity to inhibit viral protein binding and exhibits functional similarity to pharmaceutical heparin, with reduced anticoagulant activity [73]. Structural analyses have revealed the presence of minor disaccharide motifs bearing N-sulfate groups at the glucosamine residue, which appear to be critical for antiviral activity [74]. Notably, acharan sulfate and related sulfated GAGs inhibit the binding of the SARS-CoV-2 spike protein to the ACE2 receptor, thereby preventing viral entry into host cells [14][15]. Surface plasmon resonance studies further indicate that antiviral efficacy increases with chain length and degree of sulfation, with octasaccharides exhibiting greater activity than shorter oligomers [74]. Although these findings are mechanistically informative, they remain preliminary and do not yet establish clinical efficacy against COVID-19 or other viral infections.
In addition to terrestrial species, marine gastropods contribute a diverse array of antiviral secondary metabolites. Extracts from Babylonia spirata, Buccinulum corneum, Buccinum undatum, Littorina littorea, Haliotis laevigata, Haliotis rubra, Murex pectin, Tegula gallina, Conus magus, and Rapanavenosa have yielded compounds with documented antiviral activity[75]. Among these, L-amino acid oxidases (LAAOs) isolated from marine mollusks have demonstrated efficacy against a broad spectrum of enveloped viruses, largely through peroxide-mediated oxidative mechanisms and envelope destabilization[76][77][78][79][80]. Hemocyanins derived from Rapanavenosa mucus have also shown inhibitory activity against herpes simplex virus type 1 (HSV-1) and human immunodeficiency virus type 1 (HIV-1), further expanding the antiviral repertoire of gastropod-derived biomolecules [81].
Taken together, these findings indicate that snail mucus contains multiple molecular classes with antiviral potential, including AMPs, sulfated glycosaminoglycans, oxidative enzymes, and glycoproteins. Antiviral activity appears to be mediated primarily through interference with viral entry, envelope destabilization, and oxidative inactivation, rather than through direct inhibition of viral replication machinery. However, the antiviral literature on snail mucus remains fragmented and methodologically heterogeneous, with a heavy reliance on in silico predictions and in vitro binding assays. Experimental validation in physiologically relevant models, standardized antiviral screening protocols, and systematic structure–activity correlation studies are essential to clarify the therapeutic relevance of mucus-derived antiviral molecules and to assess their translational viability.
4. ANTIMICROBIAL ACTIVITY OF NANOPARTICLES SYNTHESIZED FROM SNAIL MUCUS
The integration of snail mucus into green nanotechnology has introduced a biologically mediated route for fabricating antimicrobial nanomaterials with enhanced functionality and reduced environmental impact. Rich in mucins, peptides, and protein fractions, snail mucus can simultaneously act as a reducing, capping, and stabilizing agent during nanoparticle synthesis, enabling the formation of metallic and carbonaceous nanostructures under mild reaction conditions [26][27][29]. This biogenic approach yields nanoparticles that are functionally coated with a biological corona derived from mucus macromolecules, which modulates their physicochemical properties and biological interactions.
Comprehensive characterization studies employing UV-Vis spectroscopy, FT-IR, SDS-PAGE, X-ray diffraction, electron microscopy (SEM/EDS, HR-TEM), atomic force microscopy, and MALDI-TOF mass spectrometry have confirmed the successful formation of mucus-mediated nanostructures and elucidated the molecular interactions underpinning nanoparticle stabilization [26][27][29]. These analyses consistently reveal that peptide and mucin functional groups bind to nanoparticle surfaces, forming a stabilizing shell that enhances colloidal stability and influences surface charge. Proteomic profiling further indicates that high-molecular-weight fractions (>30 kDa) are preferentially involved in nanoparticle nucleation and stabilization, suggesting a selective role for specific mucus macromolecules in nanofabrication [28]
Mucus-derived nanoparticles exhibit broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, although efficacy varies according to nanoparticle composition, size distribution, surface chemistry, and the mucus fraction employed during synthesis. Gold nanoparticles conjugated with mucins from Eobania vermiculata display enhanced inhibitory effects against Escherichia coli, a phenomenon attributed to protein-mediated surface functionalization that improves bacterial adhesion and membrane interaction [25]. Similarly, silver nanoparticles synthesized from the mucus of Helix aspersa, Eobania vermiculata, and Achatina fulica inhibit the growth of Staphylococcus aureus and E. coli with IC?? values in the range of 10–15 μM, while exhibiting moderate selectivity indices for eukaryotic model cells, indicating low to moderate cytotoxicity[29][36]. Copper oxide nanoparticles produced via mucus-mediated reduction demonstrate particularly strong activity against Gram-positive bacteria, consistent with enhanced electrostatic interactions between cationic nanoparticle surfaces and the anionic cell walls of these organisms [26].
The physicochemical tuning of mucus-derived nanoparticles can further amplify antimicrobial performance. Co-synthesis in the presence of redox agents such as ascorbic acid yields smaller, more uniformly distributed nanoparticles with increased surface reactivity and penetration capacity[26][82]. These hybrid formulations significantly enhance antibacterial efficacy, particularly against Gram-negative bacteria, which are otherwise more tolerant to metal nanoparticles due to the protective barrier conferred by their outer membrane. For example, ascorbate-assisted copper oxide and silver nanoparticles exhibit up to 30-45% greater inhibitory activity against Gram-negative strains relative to mucus-only formulations[36][82].
Beyond metallic systems, non-metallic nanomaterials synthesized using snail mucus have also demonstrated antimicrobial potential. The combination of nanodiamonds with mucus-derived peptide fractions yields synergistic antibacterial effects, particularly when high-molecular-weight peptides are employed [28]. Fluorinated graphene nanosheets fabricated using Lissachatina fulica mucus exhibit broad-spectrum antimicrobial activity against E. coli, Bacillus subtilis, Klebsiella pneumoniae, and Pseudomonas aeruginosa at low concentrations, underscoring the versatility of mucus as a biological functionalization matrix for diverse nanomaterial platforms[29].
Mechanistically, the antimicrobial activity of mucus-mediated nanoparticles reflects the convergence of multiple interacting processes. These include electrostatic adsorption onto bacterial surfaces, disruption of membrane integrity, controlled release of antibacterial metal ions, and induction of oxidative stress through reactive oxygen species generation[83][84]. The biological corona formed by mucus macromolecules plays a critical role in modulating these effects by stabilizing nanoparticles in colloidal suspension, enhancing biocompatibility, and regulating ion release kinetics[83][84][85]. In addition, synergistic interactions between nanoparticle cores and mucus-derived peptides or mucins further amplify antimicrobial efficacy through combined membranolytic and oxidative mechanisms.
Collectively, these findings highlight the dual function of snail mucus as both a biological reducing agent and a stabilizing matrix for nanomaterial synthesis. Mucus-derived macromolecules modulate nanoparticle size, surface charge, and colloidal stability, thereby enhancing antimicrobial performance while mitigating cytotoxicity. Comparative evidence indicates that hybrid systems generated using mucus in combination with auxiliary redox agents such as ascorbate consistently outperform mucus-only formulations, particularly against Gram-negative bacteria. However, antimicrobial efficacy remains highly sensitive to physicochemical parameters, including particle size, polydispersity, surface chemistry, and protein corona composition. Systematic structure–activity correlation studies and standardized biosafety benchmarking are therefore essential to rationalize nanomaterial design and to advance mucus-mediated nanoparticles toward clinically viable antimicrobial platforms.
5. PEPTIDES, PROTEINS, AND BIOACTIVE CONSTITUENTS OF SNAIL MUCUS: STRUCTURAL DIVERSITY AND ANTIMICROBIAL FUNCTIONS
Snail mucus constitutes a chemically complex secretion enriched in peptides, proteins, glycoproteins, lectins, enzymes, polysaccharides, and low-molecular-weight metabolites that collectively contribute to the innate immune defense of snails[11]. This molecular diversity underpins the broad-spectrum antimicrobial activity of mucus and reflects evolutionary adaptation to continuous microbial exposure. Advances in proteomics, peptidomics, and glycomics have begun to resolve the compositional complexity of mucus, revealing a multilayered antimicrobial architecture in which low-molecular-weight peptides, high-molecular-weight glycoproteins, and oxidative enzymes act synergistically.
5.1. Low-molecular-weight antimicrobial peptides.
Low-molecular-weight peptide fractions constitute a central antimicrobial component of snail mucus. In Helix aspersa and Helix lucorum, glycosylated peptides of approximately 4.0 and 6.4 kDa have been isolated from the 2–10 kDa fraction and exhibit marked antibacterial activity [42][86]. These peptides are enriched in glycine and proline residues, which promote conformational flexibility and structural stability while facilitating membrane interaction. Broader peptidomic analyses of Cornu aspersum mucus have identified peptide families dominated by glycine, leucine, valine, proline, tryptophan, glutamic acid, aspartic acid, phenylalanine, and arginine residues, conferring amphipathic, cationic properties characteristic of classical antimicrobial peptides (AMPs) [35].
AMPs isolated from multiple snail species fall primarily into two structural classes: α-helical cationic peptides rich in alanine, leucine, and lysine residues, and flexible proline-rich peptides enriched in proline, tryptophan, histidine, arginine, and glycine residues[87]. The former typically disrupt bacterial membranes through pore formation and bilayer destabilization, whereas the latter exert antibacterial effects by interfering with intracellular targets, including ribosomal translation machinery, particularly in Gram-negative bacteria. Comparative sequence analyses indicate homology between mucus-derived peptides and established AMP families such as microcins, leptoglycins, ctenidins, holotricins, and acanthoscurrins, suggesting evolutionary conservation of antimicrobial motifs[72][88].
Recent proteomic investigations have further expanded the AMP repertoire of snail mucus, identifying at least 16 novel antimicrobial peptides in the 3–10 kDa range that exhibit strong antibacterial and antifungal activity [73]. These peptides are highly enriched in glycine, leucine, valine, proline, tryptophan, and arginine residues, forming a new AMP class with pronounced amphipathic and cationic character. Fractionated mucus preparations containing peptides below 20 kDa display particularly high antimicrobial potency, with inhibitory indices exceeding 7,700 mm²/mg protein/μmol in standardized assays [89].
5.2. High-molecular-weight proteins and glycoproteins.
In addition to AMPs, snail mucus contains a diverse array of high-molecular-weight antimicrobial proteins and glycoproteins that contribute to oxidative, agglutinating, and immunomodulatory defense mechanisms. Among the best-characterized is achacin, a 160 kDa glycoprotein isolated from Achatina fulica mucus that comprises two subunits of approximately 70-80 kDa and exhibits potent antibacterial activity through its L-amino acid oxidase (LAAO) function [90][91]. Achacin catalyzes the oxidative deamination of L-amino acids, generating localized hydrogen peroxide that exerts bactericidal effects while remaining spatially constrained to microbial surfaces.
The antibacterial efficacy of achacin is further enhanced by AfHML, a 78 kDa lectin also secreted by A. fulica, which induces agglutination of Gram-positive and Gram-negative bacteria and increases local oxidative stress by concentrating LAAO activity at the bacterial envelope [90][91][92]. Additional antimicrobial proteins identified in A. fulica mucus include Achatin CRP (C-reactive protein), hemocyanin β c-HaH, mytimacin-AF (a cysteine-rich peptide of approximately 9.7 kDa containing five disulfide bridges), and several proteins in the 10-85 kDa range[59][90][93][94]. These macromolecules contribute to antibacterial, antifungal, and immunomodulatory activity through mechanisms involving agglutination, oxidative stress induction, and membrane destabilization.
Proteomic analyses of Helix aspersa mucus reveal a distinct protein profile relative to A. fulica. Electrophoretic separation identifies dominant protein bands in the 30-40 kDa and 50-60 kDa ranges, as well as lectins of approximately 12 kDa and glycoproteins comprising two subunits of 71-73 kDa[95][96][97]. Aspernin, a protein of approximately 37.5 kDa, exhibits homology with agglutinins from H. aspersa and H. pomatia, whereas a 52.9 kDa protein shares strong similarity with mucus proteins from Candidulaunifasciata[73]. These findings indicate that species-specific protein repertoires contribute substantially to interspecies variability in antimicrobial efficacy.
Extracellular matrix glycoproteins also represent a major structural and functional component of snail mucus. Mucins such as MUC5AC, MUC5B, MUC2, and MUC17 account for up to 40-50% of total mucus protein content and play a dual role in lubrication and antimicrobial defense[73]. Through synergistic interactions with lectins, hemocyanins, and oxidative enzymes, mucins facilitate pathogen trapping, membrane destabilization, and sustained antimicrobial activity at epithelial surfaces[73].
5.3. Polysaccharides, oxidative enzymes, and secondary metabolites.
Beyond peptides and proteins, snail mucus contains sulfated polysaccharides, notably acharan sulfate, which exhibit antiviral and immunomodulatory properties through interference with viral protein binding and host-virus interactions [90]. Glycosaminoglycans, glycoconjugates, and calcium ions further contribute to antimicrobial defense by modulating mucus rheology, ionic strength, and microbial adhesion dynamics [98].
Oxidative enzymes constitute an additional antimicrobial layer. Cu/Zn superoxide dismutase (CrCu/Zn-SOD), a 180 kDa enzyme identified in snail mucus, exhibits pronounced antibacterial activity against E. coli, S. typhi, and S. aureus, likely through redox perturbation and interference with bacterial oxidative stress defenses[99]. LAAOs, including achacin, similarly generate localized hydrogen peroxide that exerts potent bactericidal effects without inducing widespread host tissue damage.
Chemical analyses have revealed the presence of volatile and lipid-derived compounds with antibacterial activity, including 2-methylnonadecane, squalene, esters, aldehydes, ketones, and sulfur-containing siloxanes[61]. Additional low-molecular-weight bioactives include allantoin, glycolic acid, achatinine, and achactin, which contribute to antimicrobial, wound-healing, and immunomodulatory functions [92][100]. Short peptides comprising fewer than 10 amino acids and enriched in lysine, arginine, valine, isoleucine, tryptophan, phenylalanine, and proline residues have also been reported as novel natural antibiotics with broad-spectrum antibacterial activity [92].Table 3 represents the different known bioactive peptides and proteins that have been identified in the mucus and bioactive fractions of different snail species.
Table 3: Bioactive peptides and proteins identified in the mucus and bioactive mucus-derived fractions across different snail species
|
Snail species |
Mucus protein/peptide |
Amino acid chain |
Molecular mass |
Ref |
|
Helix aspersa |
Hemocyanin β c-HaH |
VRKNVDKLTKDELYDLQRALRDVVA |
- |
[101] |
|
Mucus |
LGHDVH |
Mucus fractions compound Mw <1 kDa |
[102] |
|
|
Mucus |
LFSNQLFN |
|||
|
Mucus |
DQDSHPYSGP |
|||
|
Mucus |
LGLGNGGAGGGLVGG |
|||
|
Mucus |
NNTVCGV |
|||
|
Mucus |
LLMGPEV |
|||
|
Mucus |
AAGLAGAGNGGG |
|||
|
Mucus |
ACAATCGVEDGV |
|||
|
Achatinafulica |
Mytimacin-AF |
TDTNVIGECFDEWSRCHRQTRWW TKILFQSCENR CKCKVQLMGNCIKVPFKCFLWKQK RFMCECYGPISG TKPWYCGWEL |
|
[93] |
|
Achacin |
MLLLNSALFILCLVCWLPGTSSSRVL TRREGPQCSRSVDV |
- |
[54] |
|
|
NLAGYYLKKLTGFDGEVLTIPQANKL EVDDGRKLYQLTVD |
- |
|||
|
EALDKVGTPEGKEFLKAFSTGNTEFIE GVSAVNYFLVELGE |
- |
|||
|
AVVGAGPSGTYSAYKLRNKGQTVEL FEYSNRIGGRLFTTH |
- |
[55] |
||
|
LPNVPDLNLESGGMRYFKNHHKIFG VLVKELNLSNKEFTE |
- |
|||
|
GFGKPGRTRFFARGKSLTLEEMTSG DVPYNSTEEKANQA |
- |
|||
|
REEEILTLTDGMSALPQALADAFLKS STSHALTLNRKLQSL |
- |
|||
|
SKTDNGLYLLEFLETNTHEGYTEESNI TDLVCARKVILAIPQ |
- |
[103] |
||
|
SALIHLDWKPLRSETVNEAFNAVKFI PTSKVFLTFPTAWW |
- |
|||
|
LSDAVKNPAFVVKSTSPFNQMYDW KSSNVTGDAAMIAS |
- |
|||
|
YADTSDTKFQENLNSKGELIPGSAPG ANRVTVALKEELLS |
- |
|||
|
QLSQAYGIERSDIPEPKSGTSQFWSS YPFEGDWTVWKAG |
- |
|||
|
YHCEYTQYIIERPSLIDDVFVVGSDH VNCIENAWTESAFLS |
- |
|||
|
VENVFEKYF |
- |
|||
|
Mucus |
KRATVYR |
- |
[104] |
|
|
Mucus |
KRLHVIG |
- |
||
|
Mucus |
LATVTVPR |
- |
||
|
Mucus |
LAIVGHKR |
- |
||
|
Mucus |
VIIAH |
- |
||
|
Mucus |
VRIKL |
- |
||
|
Cornu aspersum |
Mucus |
MGVGAVWNGH K |
- |
[67]
|
|
Mucus |
MLGGGVNSLRPPK |
- |
||
|
Mucus |
MLNVAVNKGEVKH |
- |
||
|
Mucus |
NLVGGLSGGGRGGAPGGGG |
- |
||
|
Mucus |
LLLDGFGGGLLVEHDPGS |
- |
||
|
Mucus |
MPKRALGGGLVGGLLGGGGEGLLVN |
- |
||
|
Mucus |
LGHDVH |
Mucus |
[35]
|
|
|
Mucus |
AAGLAGAGNGGG |
|||
|
Mucus |
LLFSGGGQFNG |
|||
|
Mucus |
LGLGNGGAGGGLVGG |
|||
|
Mucus |
LNLGLDAGGGDPGG |
|||
|
Mucus |
GAACNLEDGSCLGV |
|||
|
Mucus |
NLVGGLSGGGRGGAPPGG |
|||
|
Mucus |
LGGLGGGGAGGGGLVGEPG |
|||
|
Mucus |
NLVGGLSGGGRGGAPGGGGG |
|||
|
Mucus |
GLLGGGGGAGGGGLVGGLLNG |
|||
|
Mucus |
MGGLLGGVNGGGKGGGPGAP |
|||
|
Mucus |
LFGGHQGGGLVGGLWRK |
|||
|
Mucus |
NGLFGGLGGGGHGGGGKGPGEGGG |
|||
|
Mucus |
LLLLMLGGGLVGGLLGGGGKGGG |
|||
|
Mucus |
PFLLGVGGLLGGSVGGGGGGGGAPL |
|||
|
Mucus |
LPFLGLVGGLLGGSVGGGGGGGGPAL |
|||
|
Mucus |
DVESLPVGGLGGGGGGAGGGGLVGGNLGGGAG |
|||
|
Mucus |
DLTLNGLS P K |
Mucus fractions compound Mw <3 kDa |
[105] |
|
|
Mucus |
M PDGALLGGGGD |
|||
|
Mucus |
DG PADNAQGAVG |
|||
|
Mucus |
SLEERDIQS |
|||
|
Mucus |
GGLLAAGAGGGGAAV |
|||
|
Mucus |
LGLGNGGAGGGLVGG |
|||
|
Mucus |
LNLGLDAGGGD P GG |
|||
|
Mucus |
FNHKSLPKLEN |
|||
|
Mucus |
NLVGGLSGGGRGGA P GG |
|||
|
Mucus |
LGGLGGGGAGGGGLVGE P G |
|||
|
Mucus |
NLVGGSGGGRGGAN P LG |
|||
|
Mucus |
NG P NGGLGGSLVNGD P K |
|||
|
Mucus |
GLLGGGGGAGGGGLVGGLLNG |
|||
|
Mucus |
MGGLLGGVNGGGKGGGG P GA P |
|||
|
Mucus |
MLLNAKWAPHSTG PP NA |
|||
|
Mucus |
LPFLGLVGGLLGGSVGGGGGGGG P AL |
|||
|
Mucus |
DVESLPVGGLGGGGGGAGGGGLVGGNLGGGAG |
|||
|
Mucus |
MLGGGWNPPK |
Mucus fractions compound Mw <1 kDa |
[86] |
|
|
Mucus |
MLGGVLGGGPLK |
|||
|
Mucus |
MGGLLGGGGVGGGSLVGPGAP |
|||
|
Mucus |
LFGGHQGGGLVGGLWRK |
|||
|
Mucus |
MGGWGGLGGGHNGGWMPPK |
|||
|
Mucus |
MPKGGGLVGGLLGDWMGHK |
|||
|
Mucus |
MVNLALVGGLLGGKCLAPAR |
|||
|
Mucus |
ENLGGGLVGGLLGGWFLHDPK |
|||
|
Mucus |
HAFDVAVGGLLGGGGAGGGGLVGGGGLGGGGA |
|||
|
Mucus |
LLPFKEPDL |
Mucus fractions compound Mw <3 kDa |
[73] |
|
|
Mucus |
ACGATLQLENCG |
|||
|
Mucus |
LNLGGNGANGLVGG |
|||
|
Mucus |
AGVGGAAGNPSTYVG |
|||
|
Mucus |
GGGMVKEDGSCLGV |
|||
|
Mucus |
MLGGGVNSLRPPK |
|||
|
Mucus |
CVGGAGGHGDSCAKGT |
|||
|
Mucus |
GGGGYHTWGEGGKF |
|||
|
Mucus |
MLNVAVNKGEVKH |
|||
|
Mucus |
NLVGGSGGGGRGGANPLG |
|||
|
Mucus |
GTMSPAGGEMGPVTAGVG |
|||
|
Mucus |
GTKGCGPGSCPPGDTVAGVG |
|||
|
Mucus |
ACSLLLGGGGVGGGKGGGGHAG |
|||
|
Mucus |
LLLDGFGGGLVEHDPGS |
|||
|
Mucus |
MGGWGGLGGGHNGGWMPPK |
|||
|
Mucus |
ACLTPVDHFFAGMPCGGGP |
|||
|
Mucus |
NGLFGGLGGGGHGGGGKGPGEGGG |
|||
|
Mucus |
LLLDNKGGGLVGGLLGGGGKGGG |
|||
|
Mucus |
GMVLLHCSPALDFHKTPAV |
|||
|
Mucus |
LPFLLGVGGLLGGSVGGGGGGGGAPL |
|||
|
Mucus |
MVLDGKGGGGLGGVLGGGKDAHLGG |
|||
|
Mucus |
LLKDNGVGGLLGGGGAGGGGLVGGNLGGGGAG |
|||
|
Mucus |
KTSKLMVYLAGGGGGLLGGVGGGGGGAGGGGPGGL |
|||
|
Mucus |
AAGLAGAGGGGGG |
3 kD |
[89] |
|
|
Mucus |
DKGLGGFEA |
|||
|
Mucus |
LGDLNAEFAAG |
|||
|
Mucus |
AGVGAGGANPSTYVG |
|||
|
Mucus |
GAACNLEDGSCLGV |
|||
|
Mucus |
EPGGGGGEGGGLLGVAL |
|||
|
Mucus |
LGPLYDEMGPVGGDVG |
|||
|
Mucus |
ASKGCGPGSCPPGDTVAGVG |
|||
|
Mucus |
ACSLLLGGGGVGGGKGGGGHAG |
|||
|
Mucus |
ACLTPVDHFFAGMPCGGGP |
|||
|
Mucus |
NGLFGGLGGGGHGGGGKGPGEGGG |
|||
|
Mucus |
LLLLMLGGGLVGGLLGGGGKGGG |
|||
|
Mucus |
PFLLGVGGLLGGSVGGGGGGGGAPL |
|||
|
Mucus |
GMVVKHCSAPLDSFAEFAGA |
|||
|
Mucus |
GLLGGGGGAGGGGLVGGLLNG |
|||
|
Mucus |
MGGLLGGVNGGGKGGGPGAP |
|||
|
Mucus |
LGNVAFTAAFTEDTSVAEGR |
17 kDa |
[97] |
|
|
Mucus |
ANLLSGLLKTVVGLVGGLVKGDEVYVK |
17 kDa |
||
|
Mucus |
GTYLALDYL |
50 kDa |
||
|
Mucus |
WWLVnLLmLVnESGSLGPPK |
50 kDa |
||
|
Mucus |
WWLVDLLFLVDESGSLGPPK |
50 kDa |
||
|
Mucus |
FGAVTFSDR |
50 kDa |
||
|
Mucus |
VFDWGVTTLNK |
50 kDa |
||
|
Mucus |
LVLVTDGNSDSFLTNAAANLQK |
50 kDa |
||
|
Mucus |
VVCGTWWDTLMYR |
30–40 kDa |
||
|
Mucus |
QYLQVTWSSPR |
30–40 kDa |
||
|
Mucus |
VGGEDAYYK |
30–40 kDa |
||
|
Mucus |
TNLGGLSSVHNEEGVVSCR |
30–40 kDa |
||
|
Mucus |
ATVGDLVKF |
30–40 kDa |
||
|
Mucus |
KLAKVF |
30–40 kDa |
||
|
Mucus |
ATAGDLVKF |
30–40 kDa |
||
|
Mucus |
TAGDLVKF |
30–40 kDa |
||
|
Mucus |
CGLEDEGLTGVSR |
30–40 kDa |
||
|
Mucus |
DVANTKNLRY |
30–40 kDa |
Taken together, these data indicate that snail mucus embodies a multilayered antimicrobial system in which low-molecular-weight peptides, high-molecular-weight glycoproteins, oxidative enzymes, polysaccharides, and secondary metabolites act in concert. Antimicrobial efficacy does not derive from a single dominant molecule but rather from synergistic interactions among structurally diverse components with complementary modes of action. Species-specific differences in peptide composition, protein repertoires, and mucin abundance underpin the pronounced interspecies variability in antimicrobial potency. These observations underscore the importance of integrative multi-omics approaches and systematic structure–activity correlation studies to resolve functional relationships within the mucus molecular network and to enable rational selection of biomolecular fractions for translational development.
6. MECHANISMS OF ACTION OF SNAIL MUCUS ON MICROBIAL PATHOGENS
The antimicrobial activity of snail mucus arises from complex and synergistic interactions among its diverse bioactive components, including antimicrobial peptides, oxidative enzymes, lectins, glycoproteins, polysaccharides, and, in hybrid systems, biogenic nanoparticles [35][15][73][29][49]. Rather than operating through a single dominant pathway, mucus-derived antimicrobial effects reflect the convergence of membranolytic, oxidative, metabolic, and virulence-inhibitory mechanisms that collectively disrupt microbial viability and pathogenicity.
6.1. Membrane-targeting and intracellular actions of antimicrobial peptides.
Antimicrobial peptides (AMPs) constitute a primary mechanistic driver of mucus-mediated antibacterial activity. Their cationic and amphipathic properties promote electrostatic attraction to negatively charged bacterial membranes, followed by insertion into the lipid bilayer and subsequent membrane destabilization [104][105]. Depending on peptide structure and length, AMPs operate through several mechanistic models, including barrel-stave pore formation, toroidal pore formation, and carpet-like membrane solubilization. These processes result in membrane permeabilization, depolarization, and cytoplasmic leakage, culminating in bacterial lysis.
Beyond membrane disruption, certain mucus-derived peptides penetrate into bacterial cells and interfere with essential intracellular targets. Proline-rich AMPs, in particular, inhibit protein synthesis by binding to the 70S ribosome and disrupting translational machinery, a mechanism especially effective against Gram-negative bacteria [87][105]. Short amphipathic peptide sequences comprising five to eight amino acids, enriched in arginine, lysine, and histidine residues, have been computationally predicted and experimentally validated to exhibit strong antibacterial and antibiofilm activity with low cytotoxicity [104]. Cationic dipeptides derived from cysteine–lysine, arginine–cysteine, and histidine–cysteine motifs similarly induce membrane disruption and demonstrate in vivo efficacy against enterohemorrhagic E. coli in Caenorhabditis elegans, reinforcing the therapeutic relevance of minimal AMP motifs [104].
6.2. Oxidative mechanisms mediated by L-amino acid oxidases and redox enzymes.
L-amino acid oxidases (LAAOs), exemplified by achacin from Achatina fulica mucus, contribute a potent oxidative antimicrobial mechanism through the localized generation of hydrogen peroxide during amino acid oxidation [55][106][79][107]. Unlike nonspecific peroxide exposure, LAAOs bind preferentially to microbial surfaces, thereby concentrating reactive oxygen species at the bacterial envelope and enhancing bactericidal efficacy while minimizing host tissue toxicity. Achacin exhibits selective binding to bacteria in active growth phases and displays stronger affinity for Staphylococcus aureus than for Escherichia coli, reflecting differential glycan recognition at microbial surfaces [38][108][79].
The antibacterial activity of LAAOs correlates not with bulk hydrogen peroxide concentration but with its localized production at the bacterial interface. This spatial confinement explains how relatively low environmental peroxide levels can exert disproportionately strong bactericidal effects [55][106]. Glycan-mediated interactions appear to modulate LAAO affinity for microbial cells, and enzymatic desialylation reduces antibacterial efficacy, underscoring the functional importance of carbohydrate recognition in oxidative antimicrobial defense.
Additional redox-active enzymes further amplify oxidative stress in microbial cells. Cu/Zn-type superoxide dismutase (CrCu/Zn-SOD) identified in snail mucus exhibits antibacterial activity against E. coli, S. typhi, and S. aureus, potentially by perturbing bacterial redox homeostasis and interacting with lipopolysaccharides in Gram-negative bacteria [99]. These oxidative mechanisms complement membranolytic peptide activity, creating a multilayered antimicrobial environment that limits bacterial adaptation.
6.3. Lectin-mediated aggregation and virulence inhibition.
Lectins present in snail mucus promote microbial aggregation by binding to oligosaccharide ligands on bacterial surfaces, thereby facilitating pathogen trapping and mechanical clearance [109][11]. Although lectin-mediated effects are not directly bactericidal, they reduce microbial dissemination and enhance susceptibility to co-occurring antimicrobial peptides and oxidative enzymes. AfHML, a lectin from A. fulica, exemplifies this mechanism by inducing bacterial agglutination and locally concentrating LAAO-generated hydrogen peroxide at the microbial envelope[90][92].
In addition to aggregation, mucus-derived proteins inhibit bacterial virulence factors. Semi-purified mucus fractions suppress the activity of α-hemolysin, coagulase, and biofilm-associated adhesins in S. aureus, thereby attenuating pathogenicity independently of direct bactericidal effects[15][104]. These antivirulence mechanisms are particularly relevant in chronic infections, where biofilm formation and toxin production contribute substantially to disease persistence and antibiotic tolerance.
6.4. Synergistic effects with biogenic nanoparticles.
When integrated into nanotechnological platforms, snail mucus further extends its antimicrobial mechanisms through synergy with metallic and carbonaceous nanoparticles. Biogenic nanoparticles synthesized using mucus as a reducing and stabilizing matrix exhibit enhanced antimicrobial efficacy due to combined electrostatic adsorption, membrane perturbation, controlled ion release, and oxidative stress induction[83][84]. Adsorption onto bacterial surfaces involves both electrostatic interactions and hydrogen bonding, which destabilize the lipid bilayer and increase membrane permeability, leading to leakage of intracellular contents [36].
Released metal ions, including Ag? and Cu²?, interfere with respiratory chain enzymes, bind thiol groups in proteins, and promote reactive oxygen species generation, thereby inducing oxidative damage to lipids, proteins, and nucleic acids [84]. The biological corona formed by mucus macromolecules modulates nanoparticle colloidal stability, ion release kinetics, and biocompatibility, thereby optimizing the balance between antimicrobial efficacy and cytotoxicity [85][84]. Co-synthesis with redox agents such as ascorbic acid further refines nanoparticle size and surface reactivity, significantly enhancing antibacterial performance, particularly against Gram-negative bacteria [36][82].
6.5. Gram-positive versus Gram-negative selectivity.
Differential susceptibility of Gram-positive and Gram-negative bacteria to snail mucus reflects fundamental differences in cell wall architecture. Gram-positive bacteria possess thick peptidoglycan layers enriched in negatively charged teichoic acids, which promote electrostatic attraction and retention of cationic peptides and metal nanoparticles, resulting in localized overconcentration of antimicrobial agents at the cell surface[82][32]. In contrast, Gram-negative bacteria are protected by an outer membrane rich in lipopolysaccharides that restrict nanoparticle adhesion and penetration, limiting access to intracellular targets [82][99]. Nanoparticles that penetrate Gram-negative envelopes through porins or periplasmic accumulation may precipitate metal ions into less toxic forms, thereby attenuating antibacterial efficacy.The most important methods used for snail mucus as an antimicrobial agent are shown in Figure 2.
Figure 2:The most important methods used for snail mucus as an antimicrobial agent.Important Bioactive Compounds: AMPAntimicrobial Peptides.GGlycoproteins.LMW.Low molecular weight molecules.Ha Hyaluronic acid.PProteins.AAchacin. LLectins. Key Effects on Bacteria: MD Membrane Disrupt. PPores. DDepolarization. L Ligands.ROSReactive oxygen species.VReactive oxygen species. PE Permeabilization.
Overall, the antimicrobial capacity of snail mucus emerges from synergistic interactions among membranolytic peptides, oxidative enzymes, lectins, polysaccharides, and, in hybrid systems, biogenic nanoparticles. These components collectively disrupt microbial membranes, localize oxidative stress, inhibit virulence factors, and interfere with essential metabolic processes. Antimicrobial selectivity reflects both molecular composition and microbial cell wall architecture, explaining differential efficacy against Gram-positive and Gram-negative bacteria. This multilayered mechanistic architecture confers functional redundancy and reduces the likelihood of resistance development, highlighting snail mucus as a biologically evolved antimicrobial system with translational relevance for next-generation anti-infective strategies.
7. MEDICAL AND PHARMACEUTICAL APPLICATIONS OF SNAIL MUCUS
The antimicrobial and bioactive properties of snail mucus have catalyzed increasing interest in its biomedical and pharmaceutical exploitation. Beyond its long-standing cosmetic use, contemporary research has begun to translate mucus-derived biomolecules into functional medical materials, particularly in the context of wound management, tissue regeneration, and infection control [110][111].
One of the most advanced translational applications of snail mucus is its incorporation into bioengineered wound dressings. Composite dressings integrating Helix aspersa mucus into chitosan matrices via freeze-drying and electrospinning have been developed to mimic the structural and functional architecture of human skin [111][112]. These bilayer systems typically comprise a nanofibrous layer designed to simulate the epidermal barrier and provide antimicrobial protection, coupled with a porous sublayer that emulates the dermal microenvironment and promotes fibroblast adhesion and proliferation [112]. Physicochemical analyses reveal that mucus incorporation significantly alters nanofiber diameter, pore size distribution, and surface wettability, while antimicrobial assays demonstrate inhibitory activity against multiple bacterial strains [113]. These multifunctional properties collectively support accelerated wound closure and reduced microbial colonization.
Snail mucus has also demonstrated therapeutic potential in inflammatory oral pathologies. In experimental models of periodontitis, oral administration of snail mucus at doses of approximately 250 mg/kg significantly reduced oxidative DNA damage (8-OHdG) and nuclear factor κB (NF-κB) expression, thereby attenuating inflammatory signaling and facilitating periodontal tissue repair [64]. These findings suggest that mucus-derived biomolecules exert both antimicrobial and immunomodulatory effects in inflamed mucosal environments.
The combination of snail mucus with additional biomaterials further enhances its functional performance. Films fabricated from the mucous secretions of Achatina fulica, particularly when snails are fed Lactuca sativa, exhibit improved antimicrobial properties and mechanical stability, rendering them suitable for use as biodegradable wound dressings [111]. Similarly, composite formulations comprising aloe vera, chitosan, and snail mucus display synergistic antibacterial activity against Staphylococcus aureus, with maximal efficacy observed at equimolar component ratios[114]. Spectroscopic analyses indicate chemical interactions among these constituents, reflecting the formation of integrated biopolymer networks with enhanced antimicrobial and physicochemical characteristics.
Chitosan-based films incorporating Helix aspersa mucus exhibit markedly improved extensibility, water vapor barrier properties, bioadhesive strength, cytocompatibility, and antimicrobial activity relative to mucus-free controls [115]. These functional enhancements are accompanied by modifications in crystalline structure and thermal stability, indicating that mucus-derived macromolecules act as structural modifiers as well as bioactive agents. Porous chitosan scaffolds loaded with H. aspersa extracts similarly display antibacterial activity against Staphylococcus epidermidis and Pseudomonas fluorescens, while benefiting from improved mechanical integrity and biodegradability [93].
At the molecular level, isolated mucus-derived peptides and proteins also show promise as lead compounds for anti-infective drug development. Mytimacin-AF, a cysteine-rich peptide isolated from A. fulica, exhibits targeted antibacterial activity against clinically relevant pathogens such as Klebsiella pneumoniae and represents a potential template for next-generation antimicrobial agents [93]. Additional antimicrobial peptides derived from snail secretions are currently being explored as candidates for topical and systemic therapeutic formulations, particularly in light of escalating bacterial resistance.
Preclinical and early clinical observations further support the translational relevance of snail mucus. Topical application of mucus from Archachatina marginata and Achatina fulica to infected wounds has been reported to suppress the growth of Pseudomonas, Streptococcus, and Staphylococcus species, accelerating wound healing and reducing bacterial burden in patient-derived samples [12]. Although these studies remain limited in scale, they provide proof-of-concept evidence for the direct clinical utility of mucus-based antimicrobial therapies.
Collectively, these findings indicate that snail mucus constitutes a versatile biomaterial platform with applications spanning wound dressings, regenerative scaffolds, anti-inflammatory therapies, and antimicrobial coatings. Its functional integration into biopolymer matrices enhances mechanical performance, bioadhesion, cytocompatibility, and antimicrobial efficacy, thereby supporting its suitability for biomedical deployment. However, the majority of reported applications remain at the preclinical or early translational stage. Key challenges include standardization of mucus sourcing and extraction protocols, reproducibility of biomaterial formulations, long-term stability, and comprehensive biosafety evaluation. In addition, regulatory considerations related to Good Manufacturing Practice (GMP) compliance, batch-to-batch variability, and ethical sourcing must be addressed to enable clinical-scale production. Systematic in vivo validation and controlled clinical trials will ultimately be required to establish the therapeutic efficacy, safety, and scalability of snail mucus-based medical products.
Perspectives
Although substantial progress has been made in elucidating the antimicrobial properties of snail mucus, its systematic translation into biomedical and industrial applications remains at an early stage. The multifunctional nature of mucus, encompassing peptides, glycoproteins, oxidative enzymes, polysaccharides, and secondary metabolites, positions it as a uniquely rich biological platform for anti-infective innovation. However, the complexity and variability of this secretion also present significant methodological and translational challenges that must be addressed through coordinated interdisciplinary research.
A first critical priority is the comprehensive molecular characterization of snail mucus using integrative multi-omics approaches. Advanced proteomics, peptidomics, glycomics, and metabolomics are required to accurately identify, quantify, and functionally annotate the bioactive constituents responsible for antibacterial, antifungal, and antiviral activities. Such analyses should be coupled with systematic structure–activity correlation studies to resolve functional relationships between molecular architecture, physicochemical properties, and antimicrobial potency. Importantly, species-specific variability, physiological conditions influencing mucus secretion, and dietary or environmental modulation of mucus composition must be standardized or explicitly controlled to ensure reproducibility and comparability across studies.
From a pharmaceutical development perspective, snail mucus offers multiple avenues for formulation into clinically relevant products, including topical gels, bioactive wound dressings, controlled drug delivery systems, antimicrobial coatings for medical devices, and injectable biomaterials. However, rigorous evaluation of biocompatibility, cytotoxicity, immunogenicity, and long-term stability is essential prior to clinical deployment. In addition, pharmacokinetic profiling, bioavailability assessment, and degradation dynamics must be systematically investigated to define safe and effective dosing regimens. These studies will be indispensable for bridging the gap between in vitro antimicrobial efficacy and in vivo therapeutic performance.
The integration of snail mucus into green nanotechnology represents a particularly promising frontier for antimicrobial innovation. Mucus-mediated biosynthesis of metallic and carbonaceous nanoparticles provides an environmentally benign route for fabricating hybrid antimicrobial platforms with tunable physicochemical properties. Future research should prioritize systematic correlation of nanoparticle size, morphology, surface charge, crystalline phase, and protein corona composition with biological efficacy and toxicity profiles. Such structure–function mapping will enable rational nanomaterial design and facilitate optimization of mucus–nanoparticle hybrids for targeted antimicrobial applications and biofilm prevention.
Beyond biomedical contexts, snail mucus holds potential for deployment across diverse industrial sectors, including cosmetics, agri-food preservation, environmental disinfection, and antimicrobial surface engineering. Its biodegradability, renewable origin, and multifunctional bioactivity confer advantages over synthetic antimicrobial agents. Nevertheless, industrial-scale implementation will require the development of standardized extraction and processing pipelines, quality control metrics, and Good Manufacturing Practice (GMP)-compliant production protocols. Ethical sourcing considerations and sustainability frameworks must also be incorporated to ensure responsible exploitation of gastropod resources.
Strategic research priorities.
To accelerate the translational trajectory of snail mucus-based technologies, future research should focus on four interlinked priorities:
Disclosure statement
No potential conflict of interest was reported by the author(s).
Availability of data and materials
All data and media used in this research are available upon reasonable request from the corresponding author.
The author(s) reported there is no funding associated with the work featured in this article.
[1] R. J. Fair and Y. Tor, “Antibiotics and bacterial resistance in the 21st century,” Perspect. Medicin. Chem., vol. 6, p. PMC-S14459, 2014.
[2] S. T. Odonkor and K. K. Addo, “Bacteria resistance to antibiotics: recent trends and challenges,” Int J Biol Med Res, vol. 2, no. 4, pp. 1204–1210, 2011.
[3] K. Todar, “Bacterial resistance to antibiotics (page 3),” Todar’s online Textb. Bacteriol., vol. 4, 2011.
[4] S. M. M. Iguchi, T. Aikawa, and J. J. Matsumoto, “Antibacterial activity of snail mucus mucin,” Comp. Biochem. Physiol. Part A Physiol., vol. 72, no. 3, pp. 571–574, 1982.
[5] A. Muylaert and J. Mainil, “Résistance bactériennes aux antibiotiques, les mécanismes et leur" contagiosité",” in Annales de Medecine vétérinaire, ULg-Université de Liège, Liège, Belgium, 2013.
[6] G. D. Wright, “Bacterial resistance to antibiotics: enzymatic degradation and modification,” Adv. Drug Deliv. Rev., vol. 57, no. 10, pp. 1451–1470, 2005.
[7] R. Gyawali and S. A. Ibrahim, “Natural products as antimicrobial agents,” Food Control, vol. 46, pp. 412–429, 2014.
[8] P. Dolashka et al., “Antimicrobial proline-rich peptides from the hemolymph of marine snail Rapana venosa,” Peptides, vol. 32, no. 7, pp. 1477–1483, 2011.
[9] A. A. Bahar and D. Ren, “Antimicrobial peptides,” Pharmaceuticals, vol. 6, no. 12, pp. 1543–1575, 2013.
[10] M. Saleem et al., “Antimicrobial natural products: an update on future antibiotic drug candidates,” Nat. Prod. Rep., vol. 27, no. 2, pp. 238–254, 2010.
[11] J. A. Abiona, A. Akinduti, O. A. Osinowo, and O. M. Onagbesan, “Comparative evaluation of inhibitory activity of Epiphgram from albino and normal skinned giant African land snail (Archachatina marginata) against selected bacteria isolates,” Ethiop. J. Environ. Stud. Manag., vol. 6, no. 2, pp. 177–181, 2013.
[12] M. Rashad, S. Sampò, A. Cataldi, and S. Zara, “Biological activities of gastropods secretions: snail and slug slime,” Nat. Products Bioprospect., vol. 13, no. 1, p. 42, 2023.
[13] M. Aouji et al., “Chemical composition, mineral profile, anti-bacterial, and wound healing properties of snail slime of Helix aspersa Müller,” BioMedicine, vol. 13, no. 4, p. 10, 2023.
[14] R. Mishra, T. G. Singh, R. Bhatia, and A. Awasthi, “Unveiling the therapeutic journey of snail mucus in diabetic wound care,” Naunyn. Schmiedebergs. Arch. Pharmacol., vol. 398, no. 6, pp. 6531–6560, 2025.
[15] N. Singh, A. N. Brown, and M. H. Gold, “Snail extract for skin: A review of uses, projections, and limitations,” J. Cosmet. Dermatol., vol. 23, no. 4, pp. 1113–1121, 2024.
[16] J. Rajaganapathi, S. P. Thyagarajan, and J. K. Edward, “Study on cephalopod’s ink for anti-retroviral activity.,” Indian J Exp Biol, 2000.
[17] C. López-Abarrategui et al., “Screening of antimicrobials from Caribbean Sea animals and isolation of bactericidal proteins from the littoral mollusk Cenchritis muricatus,” Curr. Microbiol., vol. 64, no. 5, pp. 501–505, 2012.
[18] M. Gayathri and S. B. Sanjeevi, “Antipathogenic activity of freshwater Gastropod Pila virens (Lamarck, 1822) from Lower Grand Anaicut Reservoir, Tamilnadu.,” Int. J. Pharm. Life Sci., vol. 5, no. 10, 2014.
[19] S. Ulagesan and H. J. Kim, “Antibacterial and antifungal activities of proteins extracted from seven different snails,” Appl. Sci., vol. 8, no. 8, p. 1362, 2018.
[20] E. Waluga-Koz?owska et al., “Snail mucus-a natural origin substance with potential use in medicine,” Acta Pol. Pharm., vol. 78, no. 6, pp. 793–800, 2021.
[21] K. Liudmyla, C. Olena, and S. Nadiia, “Chemical properties of Helix aspersa mucus as a component of cosmetics and pharmaceutical products,” Mater. Today Proc., vol. 62, pp. 7650–7653, 2022.
[22] G. Cilia and F. Fratini, “Antimicrobial properties of terrestrial snail and slug mucus,” J. Complement. Integr. Med., vol. 15, no. 3, 2018.
[23] E. Wargala, A. Zalewska, M. S?awska, and I. Kot, “Snail mucus as an innovative ingredient used in the cosmetology and medical industry,” Aesthetic Cosmetol. Med., vol. 12, no. 2, pp. 45–49, 2023.
[24] Y. B. Rosanto, C. Y. Hasan, R. Rahardjo, and T. W. Pangestiningsih, “Effect of snail mucus on angiogenesis during wound healing,” F1000Research, vol. 10, p. 181, 2021.
[25] P. Dolashka et al., “Development of CuO nanoparticles from the mucus of garden snail Cornu aspersum as new antimicrobial agents,” Pharmaceuticals, vol. 17, no. 4, p. 506, 2024.
[26] N. Noothuan, K. Apitanyasai, S. Panha, and A. Tassanakajon, “Snail mucus from the mantle and foot of two land snails, Lissachatina fulica and Hemiplecta distincta, exhibits different protein profile and biological activity,” BMC Res. Notes, vol. 14, no. 1, p. 138, 2021.
[27] A. M. Ibrahim, A. E. Gouda, H. Okasha, H. Dahroug, and M. A. Shemis, “Anti-microbial, Anti-inflammatory and Anti-cancer Potentials of Eobaniavermiculata (Müller, 1774) Mucin-conjugated Gold Nanoparticles,” Egypt. J. Med. Microbiol., vol. 33, no. 4, 2024.
[28] E. Daskalova et al., “Antibacterial activity of combined nanodiamonds and snail fractions with biocompounds with MW below 10 kDa and above 30 kDa,” in Proceedings of the Bulgarian Academy of Sciences, 2023, pp. 35–43.
[29] M. Ganesan et al., “Synthesis and characterization of fluorinated graphene oxide nanosheets derived from Lissachatina fulica snail mucus and their biomedical applications,” Luminescence, vol. 39, no. 9, p. e4875, 2024.
[30] K. Alarfaj et al., “Evaluation of the White Garden Snail (Theba pisana) Mucus Slime for its Efficacy as an Antimicrobial Agent,” J Pure Appl Microbiol, vol. 18, no. 2, pp. 900–906, 2024.
[31] N. A. EL-Zawawy and M. M. Mona, “Evaluation and comparison of antimicrobial efficacy of snail mucus of Egyptian Eremina desertorum and Helix aspersa with novel approach of their anti-inflammatory and wound healing potencies,” 2021.
[32] U. J. Adole, “Antibacterial susceptibility of Staphylococcus aureus, Salmonella typhi, Bacillus subtilis and Escherichia coli to snail slime,” Afr. Health Sci., vol. 23, no. 4, pp. 177–182, 2023.
[33] F. A. Okeniyi, O. M. Oghenochuko, S. O. Olawoye, R. A. Animashahun, A. G. Adeyonu, and O. B. Akpor, “Antimicrobial potentials of mucus mucin from different species of giant African land snails on some typed culture pathogenic bacteriab,” Asian J. Agric. Biol., vol. 2022, no. 04, 2022.
[34] A. Chuku, “Antibacterial properties of snail mucus on bacteria isolated from patients with wound infection,” Br. Microbiol. Res. J., 2016.
[35] I. G. A. A. Septiari and N. P. A. Suryaningsih, “Antibacterial Activity of Terrestrial Snail Mucus: A Review,” J. Media, Sci. Educ., vol. 3, no. 2, pp. 16–23, 2024.
[36] A. A. El-Attar et al., “Silver/Snail mucous PVA nanofibers: Electrospun synthesis and antibacterial and wound healing activities,” Membranes (Basel)., vol. 12, no. 5, p. 536, 2022.
[37] N. A. El-Zawawy and M. M. Mona, “Antimicrobial efficacy of Egyptian Eremina desertorum and Helix aspersa snail mucus with a novel approach to their anti-inflammatory and wound healing potencies,” Sci. Rep., vol. 11, no. 1, p. 24317, 2021.
[38] T. Ehara, S. Kitajima, N. Kanzawa, T. Tamiya, and T. Tsuchiya, “Antimicrobial action of achacin is mediated by L-amino acid oxidase activity,” FEBS Lett., vol. 531, no. 3, pp. 509–512, 2002.
[39] S. M. M. Iguchi, T. Aikawa, and J. J. Matsumoto, “Antibacterial activity of snail mucus mucin,” Comp. Biochem. Physiol. -- Part A Physiol., vol. 72, no. 3, pp. 571–574, 1982, doi: 10.1016/0300-9629(82)90123-2.
[40] N. Merah, M. Bouacha, Y. Benhassine, and G. Bourzama, “RESEARCH ARTICLE Antibacterial and antibiofilm properties of Helix aspersa mucus towards multidrug resistant Staphylococcus aureus,” Trop. Biomed., vol. 41, no. 4, pp. 491–497, 2024.
[41] S. J. Pitt, M. A. Graham, C. G. Dedi, P. M. Taylor-Harris, and A. Gunn, “Antimicrobial properties of mucus from the brown garden snail Helix aspersa,” Br. J. Biomed. Sci., vol. 72, no. 4, pp. 174–181, 2015.
[42] G. Cilia and F. Fratini, “Antimicrobial properties of terrestrial snail and slug mucus,” J. Complement. Integr. Med., vol. 15, no. 3, pp. 1–10, 2018, doi: 10.1515/jcim-2017-0168.
[43] N. A. EL-Zawawy and M. M. Mona, “Antimicrobial efficacy of Egyptian Eremina desertorum and Helix aspersa snail mucus with a novel approach to their anti-inflammatory and wound healing potencies,” Sci. Rep., vol. 11, no. 1, pp. 1–11, 2021, doi: 10.1038/s41598-021-03664-3.
[44] L. Etim, C. Aleruchi, and G. Obande, “Antibacterial Properties of Snail Mucus on Bacteria Isolated from Patients with Wound Infection,” Br. Microbiol. Res. J., vol. 11, no. 2, pp. 1–9, 2016, doi: 10.9734/bmrj/2016/21731.
[45] S. J. Pitt, M. A. Graham, C. G. Dedi, P. M. Taylor-Harris, and A. Gunn, “Antimicrobial properties of mucus from the brown garden snail Helix aspersa,” Br. J. Biomed. Sci., vol. 72, no. 4, pp. 174–181, 2015, doi: 10.1080/09674845.2015.11665749.
[46] D. Bortolotti, C. Trapella, T. Bernardi, and R. Rizzo, “Antimicrobial properties of mucus from the brown garden snail Helix aspersa,” Br. J. Biomed. Sci., vol. 73, no. 1, pp. 49–50, 2016.
[47] M. Aleksova, L. P. Velkova, P. Dolashka, and G. Radeva, “Antibacterial activity of bioactive fractions from mucus and hemolymph of different snails species and crab,” Bulg. Chem. Commun, vol. 53, pp. 22–26, 2021.
[48] T. I. ADESIPE, “Determination of Nutrient Composition and Antibacterial Activity 0f Snail (Archachatina marginata) Slime”.
[49] O. M. Ikeokwu, “Antimicrobial Susceptibility Test of Snail Mucin on Staphylococcus aureus and Candida albicans,” EC Microbiol., vol. 21, pp. 1–5, 2025.
[50] A. M. Ahmad, M. Ali, L. Muazu, M. S. Abdallah, and I. U. Zungum, “Assessment of antibacterial activity of snail Archachatina marginata slime on some clinical wound isolate,” Innov Int J Med Pharm Sci, vol. 6, pp. 8–11, 2021.
[51] O. M. Abiona, J. A., Akinduiti, A., Osinowo, O. A. and Onagbesan, “Comparative evaluation of inhibitory activity of Epiphgram from albino and normal skinned giant African land snail (Archachatina marginata) against selected bacteria isolates,” Ethiop. J. Environ. Stud. Manag. Vol. 6 No.2 2013 Comp., vol. 6, no. 2, pp. 177–181, 2013.
[52] W. A. Santana et al., “Evaluación de la Actividad Antimicrobiana y la Cicatrización Potencial de la Secreción Mucosa de Achatina fulica,” Int. J. Morphol., vol. 30, no. 2, pp. 365–373, 2012.
[53] L. Suárez, A. Pereira, W. Hidalgo, and N. Uribe, “Antibacterial, antibiofilm and anti-virulence activity of biactive fractions from mucus secretion of giant African snail Achatina fulica against Staphylococcus aureus strains,” Antibiotics, vol. 10, no. 12, p. 1548, 2021.
[54] H. Otsuka-Fuchino, Y. Watanabe, C. Hirakawa, T. Tamiya, J. J. Matsumoto, and T. Tsuchiya, “Bactericidal action of a glycoprotein from the body surface mucus of giant African snail.,” Comp. Biochem. Physiol. C., vol. 101, no. 3, pp. 607–613, 1992.
[55] T. Ehara, S. Kitajima, N. Kanzawa, T. Tamiya, and T. Tsuchiya, “Antimicrobial action of achacin is mediated by L-amino acid oxidase activity,” FEBS Lett., vol. 531, no. 3, pp. 509–512, 2002, doi: 10.1016/S0014-5793(02)03608-6.
[56] A. E. Pereira, A. Rey, J. P. López, J. P. Castro, and N. Uribe, “Caracterización físico-química y actividad antimicrobiana de la secreción mucosa de Achatina fulica,” Rev. la Univ. Ind. Santander. Salud, vol. 48, no. 2, pp. 188–195, 2016.
[57] S. Mukherjee, S. Barman, N. C. Mandal, and S. Bhattacharya, “Anti-bacterial activity of Achatina CRP and its mechanism of action,” Indian J Exp Biol, vol. 52, no. 7, pp. 692–704, 2014.
[58] W. A. Santana et al., “Assessment of Antimicrobial Activity and Healing Potential of Mucous Secretion of Achatina fulica,” Int. J. Morphol., vol. 30, no. 2, pp. 365–373, 2012, doi: 10.4067/s0717-95022012000200001.
[59] H. M. D. Nugrahananto, I. L. Kriswandini, and R. Ester Arijani, “Antimicrobial proteins of Snail mucus (Achatina fulica) against Streptococcus mutans and Aggregatibacter actinomycetemcomitans,” Dent. J. (MajalahKedokteran Gigi), vol. 47, no. 1, pp. 31–36, 2014.
[60] N. K. R. Gusti Agung Ayu Putu Swastini, Ni Nengah Sumerti, I. A. M. S. A. Wayan Juniarsana, I Ketut Suardana, and R. T. Ida Ayu Dewi Kumala Ratih, “Identification of active chemical compounds and potential antibacterial snail mucus (Achatina fulica) on bacteria Enterococcus foecalis causes of periodontitis,” Open Access Peer Rev. Multidiscip. J. Biol. Med. Biochem., vol. 16, no. 2, 2022.
[61] M. Anju and K. Vijayan, “Comparison of antimicrobial properties of the slime of invasive alien pest Lissachatina fulica and an indigenous pest Cryptozona bistrialis snails,” Crop Res., vol. 56, no. 5, pp. 159–164, 2021.
[62] R. L. C. SANTANA, W. A.; MELO, C. M.; CARDOSO, J. C.; PEREIRA-FILHO, R. N.; RABELO, A. S.; REIS, F. P. & ALBUQUERQUEJÚNIOR, “Assessment of antimicrobial activity and healing potential of mucous secretion of Achatina fulica,” Int. j. morphol, vol. 30, no. 2, pp. 365–373, 2012.
[63] S. Igaap and N. N. Sumerti, “Antibacterial Effects of Various Concentrations of Natural Ingredients Snail Mucus (Achatina fulica) Against Inhibition Zones of Fusobacterium nucleatum Causes Periodontitis In Vitro,” J. Heal. Med. Sci., vol. 5, no. 3, 2022, doi: 10.31014/aior.1994.05.03.235.
[64] I. Swastini and A. Widnyana, “Antimicrobial properties of snail slime (Achatina fulica) on the growth of actinobacilus actinomycetemcomitans bacteria causing periodontitis,” J. Glob. Pharma Technol, vol. 11, pp. 170–174, 2009.
[65] G. V Zodape, “A study on presence of bioactive compounds in snail Achantina fulica,” J. Appl. Nat. Sci., vol. 2, no. 2, p. 266, 2010.
[66] N. Nantarat, Y. Tragoolpua, and P. Gunama, “Antibacterial activity of the Mucus Extract from the Giant African Snail (Lissachatina fulica) and Golden Apple Snail (Pomacea canaliculata) against pathogenic bacteria causing skin diseases,” Trop. Nat. Hist., vol. 19, no. 2, pp. 103–112, 2019.
[67] A. Dolashki et al., “Structure and antibacterial activity of isolated peptides from the mucus of garden snail Cornu aspersum,” Bulg. Chem. Commun., vol. 50, no. C, pp. 195–200, 2018.
[68] G. Buda De Cesare, S. A. Cristy, D. A. Garsin, and M. C. Lorenz, “Antimicrobial peptides: a new frontier in antifungal therapy,” MBio, vol. 11, no. 6, pp. 10–1128, 2020.
[69] R. zhen Zhong and D. wei Zhou, “Oxidative stress and role of natural plant derived antioxidants in animal reproduction,” J. Integr. Agric., vol. 12, no. 10, pp. 1826–1838, 2013, doi: 10.1016/S2095-3119(13)60412-8.
[70] L. Velkova et al., “The Role of Oxidative Stress in the Antifungal Activity of Two Mollusk Fractions on Resistant Fungal Strains,” Int. J. Mol. Sci., vol. 26, no. 3, p. 985, 2025.
[71] C. López-Abarrategui et al., “Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus,” Biochimie, vol. 94, no. 4, pp. 968–974, 2012, doi: 10.1016/j.biochi.2011.12.016.
[72] Y. Topalova et al., “Effect and Mechanisms of Antibacterial Peptide Fraction from Mucus of C. aspersum against Escherichia coli NBIMCC 8785,” Biomedicines, vol. 10, no. 3, 2022, doi: 10.3390/biomedicines10030672.
[73] L. Velkova et al., “Antibacterial properties of peptide and protein fractions from Cornu aspersum mucus,” Molecules, vol. 29, no. 12, p. 2886, 2024.
[74] K. Kodchakorn, T. Chokepaichitkool, and P. Kongtawelert, “Purification and characterisation of heparin-like sulfated polysaccharides with potent anti-SARS-CoV-2 activity from snail mucus of Achatina fulica,” Carbohydr. Res., vol. 529, p. 108832, 2023.
[75] A. M. Ibrahim, A. A. Hamed, and M. A. Ghareeb, “Marine, freshwater, and terrestrial snails as models in the biomedical applications.,” Egypt. J. Aquat. Biol. Fish., vol. 25, no. 3, 2021.
[76] E. V Lukasheva and T. T. Berezov, “L-Lysine α-oxidase: physicochemical and biological properties,” Biochem., vol. 67, no. 10, pp. 1152–1158, 2002.
[77] Y.-J. Zhang et al., “Molecular characterization of Trimeresurus stejnegeri venom L-amino acid oxidase with potential anti-HIV activity,” Biochem. Biophys. Res. Commun., vol. 309, no. 3, pp. 598–604, 2003.
[78] Y. Zhao et al., “A novel heme-containing protein with anti-HIV-1 activity from skin secretions of Bufo andrewsi,” Toxicon, vol. 46, no. 6, pp. 619–624, 2005.
[79] K. Kasai, T. Ishikawa, T. Nakamura, and T. Miura, “Antibacterial properties of L-amino acid oxidase: mechanisms of action and perspectives for therapeutic applications,” Appl. Microbiol. Biotechnol., vol. 99, no. 19, pp. 7847–7857, 2015.
[80] R. Meenakshisundaram, S. Sweni, and P. Thirumalaikolundusubramanian, “Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review,” AIDS Res. Ther., vol. 6, no. 1, p. 25, 2009.
[81] M. Rashad, S. Sampò, A. Cataldi, and S. Zara, “From Nature to Nurture: The Science and Applications of Snail Slime in Health and Beauty,” J. Cosmet. Dermatol., vol. 24, no. 2, p. e70002, 2025.
[82] N. Noothuan, K. Apitanyasai, S. Panha, and A. Tassanakajon, “Snail mucus from the mantle and foot of two land snails, Lissachatina fulica and Hemiplecta distincta, exhibits different protein profile and biological activity,” BMC Res. Notes, vol. 14, no. 1, pp. 1–7, 2021, doi: 10.1186/s13104-021-05557-0.
[83] A. M. Ibrahim, T. M. Hussein, H. Abdel-Tawab, O. A. Hammam, and M. A. Ghareeb, “The ameliorative effects of Eremina desertorum snail mucin in combination with Silymarin against experimentally induced liver fibrosis,” Egypt. J. Chem., vol. 65, no. 2, pp. 181–190, 2022, doi: 10.21608/EJCHEM.2021.84043.4114.
[84] P. C. Mane et al., “Terrestrial snail-mucus mediated green synthesis of silver nanoparticles and in vitro investigations on their antimicrobial and anticancer activities,” Sci. Rep., vol. 11, no. 1, pp. 1–16, 2021, doi: 10.1038/s41598-021-92478-4.
[85] M. F. Di Filippo et al., “Effectiveness of snail slime in the green synthesis of silver nanoparticles,” Nanomaterials, vol. 12, no. 19, p. 3447, 2022.
[86] L. Velkova, A. Nissimova, A. Dolashki, E. Daskalova, P. Dolashka, and Y. Topalova, “Glycine-rich peptides from Cornu aspersum snail with antibacterial activity,” Bulg. Chem. Commun, vol. 50, pp. 169–175, 2018.
[87] L. Velkova, A. Nissimova, A. Dolashki, E. Daskalova, and P. D. Y. Topalova, “Glycine-rich peptides from Cornu aspersum snail with antibacterial activity,” Bulg. Chem. Commun., vol. 50, no. C, pp. 169–175, 2018.
[88] A. Dolashki et al., “Antimicrobial activities of different fractions from mucus of the garden snail Cornu aspersum,” Biomedicines, vol. 8, no. 9, p. 315, 2020.
[89] Y. Topalova et al., “Effect and Mechanisms of Antibacterial Peptide Fraction from Mucus of C. aspersum against Escherichia coli NBIMCC 8785,” Biomedicines, vol. 10, no. 3, p. 672, 2022.
[90] A. Alogna, A. Liboni, and R. Rizzo, “Evaluation of Biological Properties and Beneficial Effects for a Sustainable and Conscious Exploitation of Achatina fulica Snails,” Biology (Basel)., vol. 14, no. 2, p. 190, 2025.
[91] Y. Kubota, Y. Watanabe, H. Otsuka, T. Tamiya, T. Tsuchiya, and J. J. Matsumoto, “Purification and characterization of an antibacterial factor from snail mucus.,” Comp. Biochem. Physiol. C., vol. 82, no. 2, pp. 345–348, 1985.
[92] S. M. M. Iguchi, T. Momoi, K. Egawa, and J. J. Matsumoto, “An N-acetylneuraminic acid-specific lectin from the body surface mucus of African giant snail,” Comp. Biochem. Physiol. -- Part B Biochem., vol. 81, no. 4, pp. 897–900, 1985, doi: 10.1016/0305-0491(85)90085-9.
[93] J. Zhong, W. Wang, X. Yang, X. Yan, and R. Liu, “A novel cysteine-rich antimicrobial peptide from the mucus of the snail of Achatina fulica,” Peptides, vol. 39, no. 1, pp. 1–5, 2013, doi: 10.1016/j.peptides.2012.09.001.
[94] S. Mukherjee, S. Barman, S. Sarkar, N. C. Mandal, and S. Bhattacharya, “Anti-bacterial activity of Achatina CRP and its mechanism of action,” Indian J. Exp. Biol., vol. 52, no. 7, pp. 692–704, 2014.
[95] P. M. Gunn, A., Pitt, S. J., Graham, M. A., Dedi, C. G., & Taylor-Harris, “Antimicrobial properties of mucus from the brown garden snail Helix aspersa,” LIVERPOOL JOHN MOORES Univ., 2018.
[96] T. Berniyanti, E. B. Waskito, and S. Suwarno, “Biochemival characterization of an antibactrial glycoprotein from Achatina fulica ferussac snail mucus local isolate and their implication on bacterial dental infection,” Indones. J. Biotechnol., vol. 12, no. 1, 2007.
[97] S. J. Pitt, J. A. Hawthorne, M. Garcia-Maya, A. Alexandrovich, R. C. Symonds, and A. Gunn, “Identification and characterisation of anti - Pseudomonas aeruginosa proteins in mucus of the brown garden snail, Cornu aspersum,” Br. J. Biomed. Sci., vol. 76, no. 3, pp. 129–136, 2019, doi: 10.1080/09674845.2019.1603794.
[98] I. G. A. A. P. Swastini et al., “Identification of active chemical compounds and potential antibacterial snail mucus (Achatina fulica) on bacteria Enterococcus foecalis causes of periodontitis,” Indonesia Journal of Biomedical Science, vol. 16, no. 2. pp. 102–105, 2022. doi: 10.15562/ijbs.v16i2.426.
[99] M. R. Habib et al., “In vitro anticancer and antimicrobial activities of copper-zinc superoxide dismutase purified from Cellana rota snail,” Egypt. J. Chem., vol. 66, no. 12, pp. 1–10, 2023.
[100] D. J. Gambin, L. O. Leal, A. P. Farina, M. A. Souza, and D. Cecchin, “Antimicrobial activity of glycolic acid as a final irrigant solution for root canal preparation,” Gen Dent, vol. 68, no. 1, pp. 41–44, 2020.
[101] P. Dolashka et al., “Antimicrobial activity of molluscan hemocyanins from Helix and Rapana snails,” Curr. Pharm. Biotechnol., vol. 17, no. 3, pp. 263–270, 2016.
[102] N. G. Vassilev et al., “An1h nmr-and ms-based study of metabolites profiling of garden snail helix aspersa mucus,” Metabolites, vol. 10, no. 9, pp. 1–15, 2020, doi: 10.3390/metabo10090360.
[103] A. E. Pereira P, A. Rey P, J. P. Lopez R, J. P. Castro O, and N. Uribe D, “Caracterización físico-química y actividad antimicrobiana de la secreción mucosa de Achatina fulica,” Revista de la Universidad Industrial de Santander. Salud, vol. 48, no. 2. pp. 188–195, 2016. doi: 10.18273/revsal.v48n2-2016003.
[104] S. Chalongkulasak, T. E-kobon, and P. Chumnanpuen, “Prediction of antibacterial peptides against propionibacterium acnes from the peptidomes of Achatina fulica mucus fractions,” Molecules, vol. 27, no. 7, p. 2290, 2022.
[105] A. Dolashki et al., “Antimicrobial Activities of Different Fractions from Mucus of the Garden Snail Cornu aspersum,” Biomedicines, vol. 8, no. 315, pp. 1–17, 2020.
[106] M. L. Lee, N. H. Tan, S. Y. Fung, and S. D. Sekaran, “Antibacterial action of a heat-stable form of L-amino acid oxidase isolated from king cobra (Ophiophagus hannah) venom,” Comp. Biochem. Physiol. Part C Toxicol. Pharmacol., vol. 153, no. 2, pp. 237–242, 2011.
[107] Y. Kitani et al., “Antibacterial action of L-amino acid oxidase from the skin mucus of rockfish Sebastes schlegelii,” Comp. Biochem. Physiol. Part B Biochem. Mol. Biol., vol. 149, no. 2, pp. 394–400, 2008.
[108] K.-C. Ko, P. C. Tai, and C. D. Derby, “Mechanisms of action of escapin, a bactericidal agent in the ink secretion of the sea hare Aplysia californica: rapid and long-lasting DNA condensation and involvement of the OxyR-regulated oxidative stress pathway,” Antimicrob. Agents Chemother., vol. 56, no. 4, pp. 1725–1734, 2012.
[109] S. Ito et al., “High molecular weight lectin isolated from the mucus of the giant African snail Achatina fulica,” Biosci. Biotechnol. Biochem., vol. 75, no. 1, pp. 20–25, 2011.
[110] E. Wargala, A. Zalewska, and I. Kot, “Snail mucus as an innovative ingredient used in the cosmetology and medical industry ?luz ?limaka jako innowacyjny sk?adnik,” vol. 12, pp. 45–49, 2023.
[111] P. de la Secreción, “Assessment of antimicrobial activity and healing potential of mucous secretion of Achatina fulica,” Int. j. morphol, vol. 30, no. 2, pp. 365–373, 2012.
[112] M. Perpelek, S. Tamburaci, A. Karakasli, and F. Tihminlioglu, “Fabrication of Bioactive Helix aspersa Extract-Loaded Chitosan-Based Bilayer Wound Dressings for Skin Tissue Regeneration,” ACS omega, vol. 9, no. 49, pp. 48070–48088, 2024.
[113] M. Perpelek et al., “Bioactive snail mucus-slime extract loaded chitosan scaffolds for hard tissue regeneration: the effect of mucoadhesive and antibacterial extracts on physical characteristics and bioactivity of chitosan matrix,” Biomed. Mater., vol. 16, no. 6, p. 65008, Sep. 2021, doi: 10.1088/1748-605X/ac2352.
[114] F. I. Muhaimin and S. E. Cahyaningrum, “Synthesis and Characterization of Aloe vera–Chitosan–Snail Mucus as Staphylococcus aureus Anti-bacterial Topical Treatment,” in Proceeding Series of International Conference on Arts and Humanities, 2022.
[115] M. F. Di Filippo et al., “Functional properties of chitosan films modified by snail mucus extract,” Int. J. Biol. Macromol., vol. 143, pp. 126–135, 2020.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications